Behcet's Disease Therapeutics Market to grow by USD 281.72 Million by 2026, 48% of the growth will originate from North America - Technavio Research Reports

NEW YORK, Nov. 8, 2022 /PRNewswire/ -- The Behcet's Disease Therapeutics Market report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years.

The potential growth difference for Behcet's disease therapeutics market between 2021 and 2026 is USD 281.72 million. 48% of the growth will originate from North America. To get the exact yearly growth variance and the Y-O-Y growth rate, Buy Sample Report.

The global Behcet disease therapeutics market is dominated by large pharmaceutical vendors such as AbbVie Inc., Novartis AG, and Johnson and Johnson with highly effective biologics that are approved for the treatment of the indication. The market is dominated by HUMIRA, a TNF inhibitor by AbbVie, while other large vendors in the market are competing with each other for increasing their market share.

• Abbvie.com - The company offers Behcet's disease therapeutics using a drug named HUMIRA which is given by injection under the skin and can be used alone, with methotrexate, or with certain other medicines.
• Amgen.com - The company offers Behcet's disease therapeutics using Otezla, the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis.
• Roche.com - The company offers Behcet's disease therapeutics using a drug named Pegasys, which is an off-label drug indicated for the treatment of Behcet.

To gain access to more vendor profiles with their key offerings available with Technavio, Click Here

Technavio categorizes the global Behcet disease therapeutics market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent, the global pharmaceuticals market covers products and companies engaged in R&D or the production of generic drugs, non-generic drugs, and veterinary drugs. 

Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. 

The following factors will drive growth in the global pharmaceuticals market: 

• Increasing life expectancy
• Improving access to better healthcare in emerging economies
• Increasing prevalence of sedentary lifestyle
• Increase in cases of chronic conditions
• Global partnerships

The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the Behcet's Disease Therapeutics Market includes the following core components:

• Inputs
• Inbound logistics
• Operations
• Outbound logistics
• Marketing and sales
• Service
• Support activities
• Innovation

To unlock information about vendor drive costs and customer service, download a free sample report.

The Behcet's disease therapeutics market share growth by the small molecules segment will be significant during the forecast period. North America will account for 48% of market growth. Behcet's disease treatments market in North America is mostly centered in the US and Canada. The market in this region will expand more slowly than the market in Asia. The market growth in North America will be facilitated by the widespread usage of off-label medications and the growing dominance of biologics.

• Product 
• Small molecules
• Biologics
• Geography 
• North America
• Europe
• Asia
• Rest of World (ROW)

Get lifetime access to our Technavio Insights! Subscribe to our "Basic Plan" billed annually at USD 5000.

Nootropics Market by Formulation and Geography - Forecast and Analysis 2022-2026: The report extensively covers the nootropics market segmentation by formulation (capsules, powder, drinks, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Breast Cancer Therapeutics Market by Product and Geography - 2022-2026: The report extensively covers the breast cancer therapeutics market segmentation by product (targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

1 Executive Summary

• 1.1 Market Overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product 
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Small molecules - Market size and forecast 2021-2026
• Exhibit 28: Chart on Small molecules - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Small molecules - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Small molecules - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Small molecules - Year-over-year growth 2021-2026 (%)

• 5.4 Biologics - Market size and forecast 2021-2026
• Exhibit 32: Chart on Biologics - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Biologics - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Biologics - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Biologics - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Product 
• Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026 
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026
• Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.11 Japan - Market size and forecast 2021-2026
• Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)

• 7.12 France - Market size and forecast 2021-2026
• Exhibit 78: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on France - Year-over-year growth 2021-2026 (%)

• 7.13 Market opportunity by geography 
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 88: Matrix on vendor position and classification

• 10.3 AbbVie Inc. 
• Exhibit 89: AbbVie Inc. - Overview
• Exhibit 90: AbbVie Inc. - Product / Service
• Exhibit 91: AbbVie Inc. - Key offerings

• 10.4 Amgen Inc. 
• Exhibit 92: Amgen Inc. - Overview
• Exhibit 93: Amgen Inc. - Product / Service
• Exhibit 94: Amgen Inc. - Key offerings

• 10.5 F. Hoffmann La Roche Ltd. 
• Exhibit 95: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 96: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 97: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 98: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 99: F. Hoffmann La Roche Ltd. - Segment focus

• 10.6 Johnson and Johnson 
• Exhibit 100: Johnson and Johnson - Overview
• Exhibit 101: Johnson and Johnson - Business segments
• Exhibit 102: Johnson and Johnson - Key news
• Exhibit 103: Johnson and Johnson - Key offerings
• Exhibit 104: Johnson and Johnson - Segment focus

• 10.7 Mitsubishi Chemical Holdings Corp. 
• Exhibit 105: Mitsubishi Chemical Holdings Corp. - Overview
• Exhibit 106: Mitsubishi Chemical Holdings Corp. - Business segments
• Exhibit 107: Mitsubishi Chemical Holdings Corp. - Key offerings
• Exhibit 108: Mitsubishi Chemical Holdings Corp. - Segment focus

• 10.8 Novartis AG 
• Exhibit 109: Novartis AG - Overview
• Exhibit 110: Novartis AG - Business segments
• Exhibit 111: Novartis AG - Key offerings
• Exhibit 112: Novartis AG - Segment focus

• 10.9 Pfizer Inc. 
• Exhibit 113: Pfizer Inc. - Overview
• Exhibit 114: Pfizer Inc. - Product / Service
• Exhibit 115: Pfizer Inc. - Key news
• Exhibit 116: Pfizer Inc. - Key offerings

• 10.10 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 119: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Key offerings

• 10.11 Viatris Inc. 
• Exhibit 121: Viatris Inc. - Overview
• Exhibit 122: Viatris Inc. - Business segments
• Exhibit 123: Viatris Inc. - Key offerings
• Exhibit 124: Viatris Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 125: Inclusions checklist
• Exhibit 126: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 127: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 128: Research methodology
• Exhibit 129: Validation techniques employed for market sizing
• Exhibit 130: Information sources

• 11.5 List of abbreviations 
• Exhibit 131: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

SOURCE Technavio